INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Endo Internatio...
November 18 2016 - 10:45PM
Business Wire
The securities litigation law firm of Brower Piven, A
Professional Corporation, announces that a class action lawsuit has
been commenced in the United States District Court for the Southern
District of New York on behalf of purchasers of Endo International
plc (Nasdaq: ENDP) (“Endo” or the “Company”) securities during the
period between September 28, 2015 and November 2, 2016, inclusive
(the “Class Period”). Investors who wish to become proactively
involved in the litigation have until January 6, 2017 to seek
appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class,
you must apply to be appointed lead plaintiff and be selected by
the Court. The lead plaintiff will direct the litigation and
participate in important decisions including whether to accept a
settlement for the Class in the action. The lead plaintiff will be
selected from among applicants claiming the largest loss from
investment in Endo securities during the Class Period. Members of
the Class will be represented by the lead plaintiff and counsel
chosen by the lead plaintiff. No class has yet been certified in
the above action.
The complaint accuses the defendants of violations of the
Securities Exchange Act of 1934 by virtue of the defendants’
failure to disclose during the Class Period that Endo’s subsidiary,
Par Pharmaceutical, had colluded with several of its industry peers
to fix generic drug prices, which constituted a violation of
federal antitrust laws, and Endo’s revenues were in part the result
of illegal conduct.
According to the complaint, following November 3, 2016 media
reports that U.S. prosecutors were considering filing criminal
charges by the end of 2016 against Par Pharmaceutical and several
other pharmaceutical companies for unlawfully colluding to fix
generic drug prices, the value of Endo shares declined
significantly.
If you have suffered a loss in excess of $100,000 from
investment in Endo securities purchased on or after September 28,
2015 and held through the revelation of negative information during
and/or at the end of the Class Period and would like to learn more
about this lawsuit and your ability to participate as a lead
plaintiff, without cost or obligation to you, please visit our
website at http://www.browerpiven.com/currentsecuritiescases.html.
You may also request more information by contacting Brower Piven
either by email at hoffman@browerpiven.com or by telephone at (410)
415-6616. Brower Piven also encourages anyone with information
regarding the Company’s conduct during the period in question to
contact the firm, including whistleblowers, former employees,
shareholders and others.
Attorneys at Brower Piven have extensive experience in
litigating securities and other class action cases and have been
advocating for the rights of shareholders since the 1980s. If you
choose to retain counsel, you may retain Brower Piven without
financial obligation or cost to you, or you may retain other
counsel of your choice. You need take no action at this time to be
a member of the class.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161118005614/en/
Brower Piven, A Professional CorporationCharles J. Piven,
410-415-66161925 Old Valley RoadStevenson, Maryland
21153hoffman@browerpiven.com
Endo (NASDAQ:ENDP)
Historical Stock Chart
From Apr 2024 to May 2024
Endo (NASDAQ:ENDP)
Historical Stock Chart
From May 2023 to May 2024